These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 32087019

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
    Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O.
    JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
    [Abstract] [Full Text] [Related]

  • 4. Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study.
    Zwan MD, Rinne JO, Hasselbalch SG, Nordberg A, Lleó A, Herukka SK, Soininen H, Law I, Bahl JM, Carter SF, Fortea J, Blesa R, Teunissen CE, Bouwman FH, van Berckel BN, Visser PJ.
    Neurology; 2016 Jan 05; 86(1):50-8. PubMed ID: 26468410
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW.
    Alzheimers Res Ther; 2019 Oct 10; 11(1):83. PubMed ID: 31601267
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid.
    Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, Shaw LM, Jagust WJ, Alzheimer's Disease Neuroimaging Initiative.
    Ann Neurol; 2013 Dec 10; 74(6):826-36. PubMed ID: 23536396
    [Abstract] [Full Text] [Related]

  • 9. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH, Cogo-Moreira H, Rabin JS, Black SE, Swardfager W, Alzheimer's Disease Neuroimaging Initiative.
    J Neurosci; 2019 Sep 11; 39(37):7428-7437. PubMed ID: 31350262
    [Abstract] [Full Text] [Related]

  • 10. Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry.
    Korecka M, Waligorska T, Figurski M, Toledo JB, Arnold SE, Grossman M, Trojanowski JQ, Shaw LM.
    J Alzheimers Dis; 2014 Sep 11; 41(2):441-51. PubMed ID: 24625802
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High-Throughput Mass Spectrometry Assay for Quantifying β-Amyloid 40 and 42 in Cerebrospinal Fluid.
    Weber DM, Tran D, Goldman SM, Taylor SW, Ginns EI, Lagier RJ, Rissman RA, Brewer JB, Clarke NJ.
    Clin Chem; 2019 Dec 11; 65(12):1572-1580. PubMed ID: 31628138
    [Abstract] [Full Text] [Related]

  • 16. Association of amyloid-β CSF/PET discordance and tau load 5 years later.
    Reimand J, Collij L, Scheltens P, Bouwman F, Ossenkoppele R, Alzheimer's Disease Neuroimaging Initiative.
    Neurology; 2020 Nov 10; 95(19):e2648-e2657. PubMed ID: 32913020
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.